Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy

Larsen, Annette K.; Bjørge, Benedikte; Klementsen, Beate; Helgeland, Lars; Wentzel‐Larsen, Tore; Fagerhol, Magne K.; Hovdenak, Nils; Dahl, Olav

doi:10.1080/02841860601099241

Cited by 30 publications

(34 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not anticipate the unavailability of one third of all patients at 1 year for follow-up because they had died, had had formation of an unplanned stoma or were receiving chemotherapy for relapse, and so bowel function could not be assessed. For the remainder, we had good completion of the data, and we were careful to extrapolate missing data only where there was a logical basis for so doing (15)(16)(17).…”

Section: Discussionmentioning

confidence: 99%

Predicting Late Effects of Pelvic Radiotherapy: Is There a Better Approach?

Wedlake

Thomas

Lalji

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Predicting Late Effects of Pelvic Radiotherapy: Is There a Better Approach?

Wedlake

Thomas

Lalji

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Eliciting symptoms accurately from patients will continue to be important for determining which patients need help. However, independent objective biomarkers of radiation toxicity, and not symptoms, will become the standard in assessing the degree of toxicity and the differences between treatments [67,68].…”

Section: How Do Pathological Changes Cause Gastrointestinal Symptoms?mentioning

confidence: 99%

“Pelvic radiation disease”: New understanding and new solutions for a new disease in the era of cancer survivorship

Andreyev

Wotherspoon

Denham

et al. 2010

Scandinavian Journal of Gastroenterology

105

View full text Add to dashboard Cite

Radiation-induced gastrointestinal toxicity is bedeviled by inappropriate terminology, causing confusion, and myth which legitimizes inappropriate clinical behavior. We must address honestly the uncomfortable reality that doctors, sometimes do harm. Not to do so in an era where survivorship is a reality, will deny millions often with severe symptoms from "pelvic radiation disease", the care which will help them.

show abstract

“…High levels of fecal calprotectin can differentiate between patients with inflammatory or neoplastic bowel diseases and those with irritable bowel syndrome or normal volunteers (Costa et al 2005). Several groups have studied the role of fecal calprotectin and lactoferrin as a biomarker of gastrointestinal toxicity after pelvic radiotherapy (Wedlake et al 2008;Larsen et al 2004Larsen et al , 2007Hille et al 2009). These fecal markers have been shown to potentially predict chronic gastrointestinal toxicity.…”

Section: Biomarkers Of Gastrointestinal Injurymentioning

confidence: 98%

Gastrointestinal Safety Pharmacology in Drug Discovery and Development

Al‐Saffar

Costa²,

Delaunois³

et al. 2015

Principles of Safety Pharmacology

View full text Add to dashboard Cite

Although the basic structure of the gastrointestinal tract (GIT) is similar across species, there are significant differences in the anatomy, physiology, and biochemistry between humans and laboratory animals, which should be taken into account when conducting a gastrointestinal (GI) assessment. Historically, the percentage of cases of drug attrition associated with GI-related adverse effects is small; however, this incidence has increased over the last few years. Drug-related GI effects are very diverse, usually functional in nature, and not limited to a single pharmacological class. The most common GI signs are nausea and vomiting, diarrhea, constipation, and gastric ulceration. Despite being generally not life-threatening, they can greatly affect patient compliance and quality of life. There is therefore a real need for improved and/or more extensive GI screening of candidate drugs in preclinical development, which may help to better predict clinical effects. Models to identify drug effects on GI function cover GI motility, nausea and emesis liability, secretory function (mainly gastric secretion), and absorption aspects. Both in vitro and in vivo assessments are described in this chapter. Drug-induced effects on GI function can be assessed in stand-alone safety pharmacology studies or as endpoints integrated into toxicology studies. In silico approaches are also being developed, such as the gut-on-a-chip model, but await further optimization and validation before routine use in drug development. GI injuries are still in their infancy with regard to biomarkers, probably due to their greater diversity. Nevertheless, several potential blood, stool, and breath biomarkers have been investigated. However, additional validation studies are necessary to assess the relevance of these biomarkers and their predictive value for GI injuries.

show abstract

Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy

Cited by 30 publications

References 37 publications

Predicting Late Effects of Pelvic Radiotherapy: Is There a Better Approach?

Predicting Late Effects of Pelvic Radiotherapy: Is There a Better Approach?

“Pelvic radiation disease”: New understanding and new solutions for a new disease in the era of cancer survivorship

Gastrointestinal Safety Pharmacology in Drug Discovery and Development

Contact Info

Product

Resources

About